Other OTC - Delayed Quote USD

Inhibitor Therapeutics, Inc. (INTI)

0.0858 +0.0288 (+50.53%)
At close: 9:39 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Francis E. O'Donnell Jr., M.D. Founder, Executive Chairman & CEO 1.09M -- 1950
Mr. James A. McNulty CPA Interim CFO, Treasurer & Secretary 337.96k -- 1950

Inhibitor Therapeutics, Inc.

900 West Platt Street
Suite 200
Tampa, FL 33606-2173
United States
813 864 2562 https://inhibitortx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
3

Description

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Corporate Governance

Inhibitor Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 14, 2024
Inhibitor Therapeutics, Inc. Earnings Call